University Of Washington

Only a decade ago, many in oncology considered chimeric antigen receptor T-cell therapy too fringe for real-world use.

Adverse events and outcomes are more common in pregnant patients with rheumatoid arthritis and systemic lupus erythematosus, and their infants, vs. those without rheumatic diseases, according to data published in Arthritis Care & Research.

NEW ORLEANS — Cumulative anesthesia exposure appeared associated with impairments in neurocognitive function among children with high-risk acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.

In an update to its guidance on primary osteoporosis, ACP recommended bisphosphonates as a first line of defense to reduce fracture risk in men and postmenopausal women.

NEW ORLEANS — Most hematopoietic stem cell transplant recipients received at least one dose of COVID-19 vaccine, according to single-institution study results presented at ASH Annual Meeting and Exposition.

Chimeric antigen receptor T-cell therapy targeting CD19 is highly effective for inducing remission among patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses research regarding novel relapsed refractory multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses noteworthy research on early-relapse multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses potentially practice-changing early research on treatments for newly diagnosed multiple myeloma presented at the ASH Annual Meeting and Exposition.

NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy conferred a 78% complete response rate in patients with heavily pretreated T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, study results showed.